126 related articles for article (PubMed ID: 38404238)
41. Stimuli-responsive PEGylated prodrugs for targeted doxorubicin delivery.
Xu M; Qian J; Liu X; Liu T; Wang H
Mater Sci Eng C Mater Biol Appl; 2015 May; 50():341-7. PubMed ID: 25746279
[TBL] [Abstract][Full Text] [Related]
42. NIR Fluorogenic Dye as a Modular Platform for Prodrug Assembly: Real-Time in vivo Monitoring of Drug Release.
Redy-Keisar O; Ferber S; Satchi-Fainaro R; Shabat D
ChemMedChem; 2015 Jun; 10(6):999-1007. PubMed ID: 25847527
[TBL] [Abstract][Full Text] [Related]
43. Drug Delivery Nanoparticles with Locally Tunable Toxicity Made Entirely from a Light-Activatable Prodrug of Doxorubicin.
Schutt C; Ibsen S; Zahavy E; Aryal S; Kuo S; Esener S; Berns M; Esener S
Pharm Res; 2017 Oct; 34(10):2025-2035. PubMed ID: 28791550
[TBL] [Abstract][Full Text] [Related]
44. A Reactivity-Tunable Self-Immolative Design Enables Histone Deacetylase-Targeted Imaging and Prodrug Activation.
Liu F; Ding X; Xu X; Wang F; Chu X; Jiang JH
Angew Chem Int Ed Engl; 2022 Nov; 61(47):e202203243. PubMed ID: 36070285
[TBL] [Abstract][Full Text] [Related]
45. Self-Assembly Dual-Responsive NO Donor Nanoparticles for Effective Cancer Therapy.
Gu G; Chen C; Zhang S; Yin B; Wang J
ACS Appl Mater Interfaces; 2021 Nov; 13(43):50682-50694. PubMed ID: 34668695
[TBL] [Abstract][Full Text] [Related]
46. Rapidly cell-penetrating and reductive milieu-responsive nanoaggregates assembled from an amphiphilic folate-camptothecin prodrug for enhanced drug delivery and controlled release.
Xu Z; Hou M; Shi X; Gao YE; Xue P; Liu S; Kang Y
Biomater Sci; 2017 Feb; 5(3):444-454. PubMed ID: 28058423
[TBL] [Abstract][Full Text] [Related]
47. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
Akinboye ES; Brennen WN; Rosen DM; Bakare O; Denmeade SR
Prostate; 2016 Jun; 76(8):703-14. PubMed ID: 26835873
[TBL] [Abstract][Full Text] [Related]
48. Prodrug based on halloysite delivery systems to improve the antitumor ability of methotrexate in leukemia cell lines.
Massaro M; Poma P; Cavallaro G; García-Villén F; Lazzara G; Notarbartolo M; Muratore N; Sánchez-Espejo R; Viseras Iborra C; Riela S
Colloids Surf B Biointerfaces; 2022 May; 213():112385. PubMed ID: 35168104
[TBL] [Abstract][Full Text] [Related]
49. Self-Distinguishing and Stimulus-Responsive Carrier-Free Theranostic Nanoagents for Imaging-Guided Chemo-Photothermal Therapy in Small-Cell Lung Cancer.
Zhu Q; Fan Z; Zuo W; Chen Y; Hou Z; Zhu X
ACS Appl Mater Interfaces; 2020 Nov; 12(46):51314-51328. PubMed ID: 33156622
[TBL] [Abstract][Full Text] [Related]
50. Ultrasound-activated prodrug-loaded liposome for efficient cancer targeting therapy without chemotherapy-induced side effects.
Jiang Y; Chen H; Lin T; Zhang C; Shen J; Chen J; Zhao Y; Xu W; Wang G; Huang P
J Nanobiotechnology; 2024 Jan; 22(1):2. PubMed ID: 38169390
[TBL] [Abstract][Full Text] [Related]
51. Redox Dual-Responsive and O
Chen H; Li F; Yao Y; Wang Z; Zhang Z; Tan N
Theranostics; 2019; 9(1):90-103. PubMed ID: 30662556
[TBL] [Abstract][Full Text] [Related]
52. Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells.
van Gisbergen MW; Cebula M; Zhang J; Ottosson-Wadlund A; Dubois L; Lambin P; Tew KD; Townsend DM; Haenen GR; Drittij-Reijnders MJ; Saneyoshi H; Araki M; Shishido Y; Ito Y; Arnér ES; Abe H; Morgenstern R; Johansson K
Mol Pharm; 2016 Jun; 13(6):2010-25. PubMed ID: 27093577
[TBL] [Abstract][Full Text] [Related]
53. Sharp pH-responsive mannose prodrug polypeptide nanoparticles encapsulating a photosensitizer for enhanced near infrared imaging-guided photodynamic therapy.
Yuan P; Ruan Z; Li T; Tian Y; Cheng Q; Yan L
J Mater Chem B; 2019 Nov; 7(43):6770-6777. PubMed ID: 31595285
[TBL] [Abstract][Full Text] [Related]
54. Emerging Strategies in Stimuli-Responsive Prodrug Nanosystems for Cancer Therapy.
Ding C; Chen C; Zeng X; Chen H; Zhao Y
ACS Nano; 2022 Sep; 16(9):13513-13553. PubMed ID: 36048467
[TBL] [Abstract][Full Text] [Related]
55. Noncovalent Theranostic Prodrug for Hypoxia-Activated Drug Delivery and Real-Time Tracking.
Zhao XB; Gao K; Shi YP
Anal Chem; 2021 Nov; 93(45):15080-15087. PubMed ID: 34743509
[TBL] [Abstract][Full Text] [Related]
56. Stimuli-Responsive Prodrug Chemistries for Cancer Therapy.
Bargakshatriya R; Pramanik SK
Chembiochem; 2023 Sep; 24(18):e202300155. PubMed ID: 37341379
[TBL] [Abstract][Full Text] [Related]
57. Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system.
Li M; Thapa P; Rajaputra P; Bio M; Peer CJ; Figg WD; You Y; Woo S
J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):521-536. PubMed ID: 28913666
[TBL] [Abstract][Full Text] [Related]
58. A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy.
Ding M; Fan Y; Lv Y; Liu J; Yu N; Kong D; Sun H; Li J
Acta Biomater; 2022 Sep; 149():334-346. PubMed ID: 35779775
[TBL] [Abstract][Full Text] [Related]
59. Intracellular Enzyme-Responsive Profluorophore and Prodrug Nanoparticles for Tumor-Specific Imaging and Precise Chemotherapy.
Pei Q; Lu S; Zhou J; Jiang B; Li C; Xie Z; Jing X
ACS Appl Mater Interfaces; 2021 Dec; 13(50):59708-59719. PubMed ID: 34879654
[TBL] [Abstract][Full Text] [Related]
60. pH/ROS dual-responsive supramolecular polypeptide prodrug nanomedicine based on host-guest recognition for cancer therapy.
Ding Y; Wang C; Ma Y; Zhu L; Lu B; Wang Y; Wang J; Chen T; Dong CM; Yao Y
Acta Biomater; 2022 Apr; 143():381-391. PubMed ID: 35272024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
